ARWR - アロ―ヘッド・リサ―チ （Arrowhead Pharmaceuticals Inc.） アロ―ヘッド・リサ―チARWRのチャート
ARWRの企業情報
| symbol | ARWR |
|---|---|
| 会社名 | Arrowhead Research Corp （アロ―ヘッド・リサ―チ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アローヘッド・ファーマシューティカル（Arrowhead Pharmaceuticals Inc）（旧名：Arrowhead Research Corporation）は生物医薬品会社である。同社はRNA干渉（RNAi）治療法の開発に従事する。同社の製品は、ARC-520、ARC-521、ARC-AAT、ARC-F12、ARC-HIF2及びARC-LPAを含む。ARC-520は、慢性B型肝炎ウイルス（HBV）感染の治療に設計される。ARC-AATは、α-1アンチトリプシン欠損症（AATD）に関連肝疾患の治療のためRNAiベースの治療薬を含むアンロック核酸塩基アナログである。ダイナミック・ポリコンジュゲート・プラットフォームは、ターゲット遺伝子ノックダウンの高レベルを促進するRNAiデリバリシステムである。ARC-F12は、遺伝性血管浮腫および血栓塞栓性疾患のために予防的治療を提供するファクター12の産生を削減するように設計されるRNAiベースの治療である。ARC-LPAは、アポリポタンパク質Aの産生を減少させるように設計されるRNAiベースの治療である。ARC-HIF2は、低酸素誘導因子2aの産生を減少ために設計されるRNAiベースの治療である。 アロ―ヘッド・リサ―チは、米国のバイオ医薬品会社。疾患を引き起こす遺伝子をRNA干渉に基づき効率的に鎮め、難治性疾患を治療する薬剤を開発。主要製品は、慢性B型肝炎の治療のためにB型肝炎ウイルスを対象とするRNA干渉基盤の治療薬ARC-520である。本社はカリフォルニア州パサディナ。 Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. |
| 本社所在地 | 225 S. Lake Avenue Suite 1050 Pasadena CA 91101 USA |
| 代表者氏名 | Douglass B. Given ダグラスB.ギブン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 626-304-3400 |
| 設立年月日 | 32782 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 104人 |
| url | www.arrowheadresearch.com |
| nasdaq_url | https://www.nasdaq.com/symbol/arwr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -50.39190 |
| 終値（lastsale） | 13.75 |
| 時価総額（marketcap） | 1210318298.75 |
| 時価総額 | 時価総額（百万ドル） 1211.198 |
| 売上高 | 売上高（百万ドル） 13.60112 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1153.09644 |
| 当期純利益 | 当期純利益（百万ドル） -54.42110 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Arrowhead Pharmaceuticals Inc revenues decreased 78% to $4.9M. Net loss increased 85% to $43.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 58% to $37M (expense) General and Administrative increase from $5.3M to $12.7M (expense). |
ARWRのテクニカル分析
ARWRのニュース
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics 2022/05/26 11:30:00 Kwhen Finance
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics 2022/05/26 11:30:00 Arrowhead Pharmaceuticals
PASADENA, Calif. --(BUSINESS WIRE)--May 26, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its
Arrowhead Pharma down 12% despite quarterly beats, swing to net gain (NASDAQ:ARWR) 2022/05/11 18:12:35 Seeking Alpha
Arrowhead Pharmaceuticals (ARWR) is down 12% in Wednesday afternoon trading despite reporting Q1 2022 results after the closing bell Tuesday that beat on the top and bottom…
Benzinga''s Top Ratings Upgrades, Downgrades For May 11, 2022 2022/05/11 14:02:45 Benzinga
Upgrades According to Roth Capital, the prior rating for Hecla Mining Co (NYSE: HL ) was changed from Neutral to Buy. In the first quarter, Hecla Mining showed an EPS of $0.01, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $9.44 and a 52-week-low of $4.28. At the end of the last trading period, Hecla Mining closed at $4.36. According to Zelman, the prior rating for The AZEK Co Inc (NYSE: AZEK ) was changed from Hold to Buy. For the second quarter, AZEK Co had an EPS of $0.33, compared to year-ago quarter EPS of $0.25. At the moment, the stock has a 52-week-high of $50.65 and a 52-week-low of $17.00. AZEK Co closed at $17.33 at the end of the last trading period. According to Maxim Group, the prior rating for Celsius Holdings Inc (NASDAQ: CELH ) was changed from Hold to Buy. In the first quarter, Celsius Holdings showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $110.22 and a 52-week-low of $38.31. At the end of the last trading period, Celsius Holdings closed at $41.31.
Here''s Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today 2021/07/02 16:18:27 The Motley Fool
A paused clinical trial with an important asset wasn''t what investors wanted to hear today.
Arrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis Treatment 2021/07/02 14:29:16 The Street
Arrowhead''s move comes after a toxicology study in rats contained unexpected signals of local lung inflammation, the company says.
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis 2021/07/02 14:24:12 Endpoints News
Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-human primate toxicology study. Now, years later and with a different delivery vehicle for its RNAi drugs, Arrowhead faces animal tox issues again in what could be
Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet 2021/07/02 12:18:00 Benzinga
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to
B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals By Investing.com 2021/03/18 15:05:10 Investing.com
B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals
Hereditary Angioedema Market to Demonstrates a Spectacular Growth with CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies 2021/03/18 06:37:38 OpenPR
Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia 2021/03/01 12:30:00 Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia
Global Hepatitis B Virus (HBV) Market Report 2021-2030 Featuring Key players | Johnson & Johnson, Merck and Co, Bristol-Myers Squibb, Gilead Sciences, Arrowhead Pharmaceuticals, Arbutus Pharma 2021/02/24 21:15:00 PR Newswire
DUBLIN, Feb. 24, 2021 /PRNewswire/ -- The "Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)" report has been added to ResearchAndMarkets.com's offering. The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030,…